← Back to patent-cliff list
Gallium (68Ga) chloride/Germanium (68Ge) chloride
Tier C — Watch / tradeGallium (68Ga) chloride/Germanium (68Ge) chloride
Novartis
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Brand：GalenVita, GalliaPharm
Indications (approved)：Neoplasm
Regional status
US
-
EU
Approved
2024-08-01
China
-
Japan
Phase III
2024-03-21
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gallium (68Ga) chloride/Germanium (68Ge) chloride?
Approved indications include: Neoplasm.
When does the Gallium (68Ga) chloride/Germanium (68Ge) chloride patent expire?
No public expiry year is available for Gallium (68Ga) chloride/Germanium (68Ge) chloride yet; this page updates once verified.
How do I get a quote for Gallium (68Ga) chloride/Germanium (68Ge) chloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27